Roflumilast - Revision history

Prab: CSV import

2025-03-23T11:05:33Z

CSV import

@@ Line 1: / Line 1: @@
-{{intro}}
+== Roflumilast ==
-Roflumilast is a selective inhibitor of phosphodiesterase-4 (PDE-4) that has unique antiinflammatory activity and is used to treat and prevent exacerbations of [[chronic obstructive pulmonary disease]] (COPD).
-{{livtox}}
+== Related Pages ==
-{{fda}}
+* [[Chronic obstructive pulmonary disease]]
-Roflumilast was approved is 2011 for use in patients with COPD to prevent acute exacerbations of chronic bronchitis.  It is currently available in tablets of 500 µg under the brand name Daliresp and the recommended dose in 500 µg once daily.
+* [[Phosphodiesterase inhibitor]]
-{{se}}
+[[Category:Phosphodiesterase inhibitors]]
-Side effects are generally mild and include diarrhea, nausea, vomiting, decreased appetite, weight loss, headache, dizziness, insomnia and back and joint pain.  Rare, but potentially severe adverse reactions include depression, suicidality and hypersensitivity reactions, including angioedema.
+[[Category:Anti-inflammatory agents]]
+[[Category:Drugs used in respiratory diseases]]

Prab: CSV import

2025-02-20T01:37:29Z

CSV import

← Older revision		Revision as of 01:37, 20 February 2025
Line 16:		Line 16:
	{{pulmonary agents}}		{{pulmonary agents}}
	{{coststubd}}		{{coststubd}}
			== Roflumilast ==
			<gallery>
			File:Roflumilast structure.svg\|Roflumilast structure
			File:Roflumilast ball-and-stick model.png\|Roflumilast ball-and-stick model
			</gallery>
	== Roflumilast ==		== Roflumilast ==
	<gallery>		<gallery>

Prab: CSV import

2025-02-20T01:13:40Z

CSV import

← Older revision		Revision as of 01:13, 20 February 2025
Line 16:		Line 16:
	{{pulmonary agents}}		{{pulmonary agents}}
	{{coststubd}}		{{coststubd}}
			== Roflumilast ==
			<gallery>
			File:Roflumilast structure.svg\|Roflumilast structure
			File:Roflumilast ball-and-stick model.png\|Roflumilast ball-and-stick model
			</gallery>

Prab: Created page with "{{intro}} Roflumilast is a selective inhibitor of phosphodiesterase-4 (PDE-4) that has unique antiinflammatory activity and is used to treat and prevent exacerbations of chr..."

2019-05-12T09:53:14Z

Created page with "{{intro}} Roflumilast is a selective inhibitor of phosphodiesterase-4 (PDE-4) that has unique antiinflammatory activity and is used to treat and prevent exacerbations of chr..."

New page

{{intro}}
Roflumilast is a selective inhibitor of phosphodiesterase-4 (PDE-4) that has unique antiinflammatory activity and is used to treat and prevent exacerbations of [[chronic obstructive pulmonary disease]] (COPD).

{{livtox}}
Roflumilast has not been linked to significant serum enzyme elevations during therapy or to instances of clinically apparent acute liver injury.

{{moa}}
Roflumilast (roe flue' mi last) is a long acting inhibitor of the enzyme, phosphodiesterase-4 (PDE-4), an oral antiinflammatory agent that is used to treat chronic obstructive pulmonary disease (COPD). PDE-4 is responsible for the metabolism of cyclic adenosine monophosphate (cAMP) and its inhibition results in increased intracellular concentrations of cAMP, an important mediator of inflammatory pathways. Roflumilast has been shown to decrease pro-inflammatory cytokines and reduce inflammatory responses in chronic pulmonary conditions including chronic bronchitis. In large controlled trials, roflumilast therapy was associated with a decrease in the numbers of severe, acute exacerbations of COPD and a modest improvement in pulmonary function test results.

{{fda}}
Roflumilast was approved is 2011 for use in patients with COPD to prevent acute exacerbations of chronic bronchitis. It is currently available in tablets of 500 µg under the brand name Daliresp and the recommended dose in 500 µg once daily.

{{se}}
Side effects are generally mild and include diarrhea, nausea, vomiting, decreased appetite, weight loss, headache, dizziness, insomnia and back and joint pain. Rare, but potentially severe adverse reactions include depression, suicidality and hypersensitivity reactions, including angioedema.

{{pulmonary agents}}
{{coststubd}}